Should I buy or sell Sangamo Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares. View SGMO analyst ratings or view top-rated stocks .

What is Sangamo Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued twelve-month price targets for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they expect the company's share price to reach $4.93 in the next year. This suggests a possible upside of 862.9% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts .

How have SGMO shares performed in 2024?

Sangamo Therapeutics' stock was trading at $0.5433 on January 1st, 2024. Since then, SGMO shares have decreased by 5.9% and is now trading at $0.5115. View the best growth stocks for 2024 here .

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SGMO earnings forecast .

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings data on Wednesday, March, 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.09. The biopharmaceutical company had revenue of $2.04 million for the quarter, compared to analysts' expectations of $8.96 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 82.17% and a negative net margin of 146.30%.

What ETFs hold Sangamo Therapeutics' stock?

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR) . Global X Genomics & Biotechnology ETF (GNOM) .

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com . Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Micron Technology (MU) , CRISPR Therapeutics (CRSP) , Novavax (NVAX) , Gilead Sciences (GILD) , Brainstorm Cell Therapeutics (BCLI) , Editas Medicine (EDIT) , Netflix (NFLX) and Intel (INTC) .

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (11.25%). Insiders that own company stock include Biogen Inc and John Markels. View institutional ownership trends .

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free SGMO Stock Alerts

$0.51

+0.03 (+6.23%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.47
▼
$0.53
50-Day Range: $0.49
▼
$1.38
52-Week Range: $0.29
▼
$1.78

Volume: 1.04 million shs
Average Volume: 2.22 million shs
Market Capitalization: $91.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.93

Get Sangamo Therapeutics alerts:

Sangamo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.29 Rating Score
Upside/Downside: 862.9% Upside
$4.93 Price Target
Short Interest: Bearish
6.38% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.54) to ($0.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.53 out of 5 stars

Medical Sector

864th out of 911 stocks

Biological Products, Except Diagnostic Industry

146th out of 150 stocks

3.1

Analyst's Opinion

Consensus Rating
Sangamo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Sangamo Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.38% of the outstanding shares of Sangamo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sangamo Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Sangamo Therapeutics has recently increased by 4.87%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Sangamo Therapeutics does not currently pay a dividend.
Dividend Growth
Sangamo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGMO.

0.0

News and Social Media Coverage

Search Interest
Only 15 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Sangamo Therapeutics is held by insiders.
Percentage Held by Institutions
56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.54) to ($0.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sangamo Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sangamo Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sangamo Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

SGMO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SGMO Stock News Headlines

April 2, 2024 | msn.com

Biotech Roundtable: Who will bring the next CRISPR drug to market?

March 25, 2024 | finance.yahoo.com

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

March 19, 2024 | money.usnews.com

Sangamo Therapeutics Inc

March 16, 2024 | ca.finance.yahoo.com

SGMO Apr 2024 1.500 put

March 16, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)

March 16, 2024 | finance.yahoo.com

SGMO Apr 2024 1.500 call

March 15, 2024 | finance.yahoo.com

SGMO Apr 2024 3.000 call

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 14, 2024 | finance.yahoo.com

Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations

March 13, 2024 | markets.businessinsider.com

Sangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy Rating

March 13, 2024 | markets.businessinsider.com

4 Analysts Assess Sangamo Therapeutics: What You Need To Know

March 13, 2024 | businesswire.com

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024 | businesswire.com

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

March 1, 2024 | finance.yahoo.com

Sangamo Therapeutics, Inc. (SGMO)

February 23, 2024 | investing.com

Sangamo Therapeutics (SGMO) Earnings Dates & Reports

February 13, 2024 | markets.businessinsider.com

Sangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial Uncertainties

February 12, 2024 | markets.businessinsider.com

Sangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920

February 12, 2024 | finance.yahoo.com

With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners

February 12, 2024 | finance.yahoo.com

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

February 7, 2024 | msn.com

Sangamo’s STAAR Study Shows Promise in Fabry Disease Treatment

February 5, 2024 | finance.yahoo.com

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

January 19, 2024 | markets.businessinsider.com

Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)

January 16, 2024 | bizjournals.com

Bay Area biotech Sangamo puts entire Peninsula headquarters up for sublease

November 30, 2023 | benzinga.com

Sangamo Therapeutics Stock (NASDAQ:SGMO) Insider Trades

November 8, 2023 | msn.com

Truist Securities Downgrades Sangamo Therapeutics (SGMO)

November 6, 2023 | msn.com

Wells Fargo Downgrades Sangamo Therapeutics (SGMO)

See More Headlines

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:SGMO
CUSIP: 80067710
CIK: 1001233
Web: www.sangamo.com
Phone: (510) 970-6000
Fax: 510-236-8951
Employees: 405
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $4.93
High Stock Price Target: $10.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +850.2%
Consensus Rating: Hold
Rating Score (0-4): 2.29
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-257,830,000.00
Net Margins: -146.30%
Pretax Margin: -149.18%
Return on Equity: -82.17%
Return on Assets: -56.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.98
Quick Ratio: 1.98

Sales & Book Value

Annual Sales: $176.23 million
Price / Sales: 0.53
Cash Flow: $0.04 per share
Price / Cash Flow: 14.01
Book Value: $0.47 per share
Price / Book: 1.10

Miscellaneous

Outstanding Shares: 178,910,000
Free Float: 173,539,000
Market Cap: $92.73 million
Optionable: Optionable
Beta: 1.39

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Alexander D. Macrae Ch.B (Age 61)
M.B., MRCP, Ph.D., CEO, President & Director
Comp: $1.17M
Ms. Prathyusha Duraibabu CPA (Age 44)
M.B.A., Senior VP, CFO & Principal Accounting Officer
Comp: $628.08k
Ms. Amy Pooler Ph.D.
Head of Research
Mr. Gregory Davis Ph.D.
Head of Technology
Ms. Aron Feingold
Head of Corporate Communications & Investor Relations Officer
Mr. Scott B. Willoughby (Age 49)
Senior VP, General Counsel & Corporate Secretary
Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)
Senior VP & Chief Development Officer
Phillip Ramsey
Head of Technical Operations
Ms. Stephanie J. Seiler CLP
Head of Business Development & Alliance Management
Mr. David Ojala
Scientist II - Discovery & Translational Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares.
View SGMO analyst ratings or view top-rated stocks.
What is Sangamo Therapeutics' stock price target for 2024?: 7 Wall Street analysts have issued twelve-month price targets for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they expect the company's share price to reach $4.93 in the next year. This suggests a possible upside of 862.9% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.
How have SGMO shares performed in 2024?: Sangamo Therapeutics' stock was trading at $0.5433 on January 1st, 2024. Since then, SGMO shares have decreased by 5.9% and is now trading at $0.5115.
View the best growth stocks for 2024 here.
When is Sangamo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SGMO earnings forecast.
How were Sangamo Therapeutics' earnings last quarter?: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings data on Wednesday, March, 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.09. The biopharmaceutical company had revenue of $2.04 million for the quarter, compared to analysts' expectations of $8.96 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 82.17% and a negative net margin of 146.30%.
What ETFs hold Sangamo Therapeutics' stock?: ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?: 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.
What other stocks do shareholders of Sangamo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).
Who are Sangamo Therapeutics' major shareholders?: Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (11.25%). Insiders that own company stock include Biogen Inc and John Markels.
View institutional ownership trends.
How do I buy shares of Sangamo Therapeutics?: Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SGMO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial